New drug candidate targets Hard-to-Treat cancers in early trial
NCT ID NCT05174637
First seen Jan 31, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This early-phase study tests an experimental drug called FDA018-ADC in people with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 78 adults aged 18-75 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200000, China
Conditions
Explore the condition pages connected to this study.